AFFY  Affymax Inc.




Consumer Durables


Major Pharmaceuticals

Market Cap.


Current Price

+0.0005 (+0.38%)

Book Price

Overvalued by 295.66%
Financial Institution

Company Metrics

  • 1.59 P/E
  • 116.04 P/S
  • 0.94 P/B
  • 0.082 EPS
  • 0.00 / N/A % Dividend
  • 141,102.00 Avg. Vol.
  • 4.9M Market Cap.

Company Description

Affymax, Inc., a biopharmaceutical company, engages in the development of drugs for the treatment of serious and life-threatening conditions. The company is developing Hematide, which is in Phase III clinical trials for the treatment of anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood ...

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Affymax, Inc. Announces a Special Cash Distribution and the Appointment of a ...
Business Wire (press release) - Nov 26, 2014
CUPERTINO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (OTCQB: AFFY) today announced that its Board of Directors has declared a special cash distribution to shareholders in the amount of $0.05 per share.
Affymax Inc.: Affymax, Inc. Announces a Special Cash Distribution And The ... - The Wall Street Transcript
Technical Insights on Affymax, Inc. (OTCMKTS: AFFY)
MicroCap Daily - Nov 3, 2014
Affymax, Inc. (OTCMKTS: AFFY) has been moving in a bearish trend since July, 2014 trading around $0.10 per share, but the stock did saw a major bullish rally in the months of January to April , 2014 when its touched its high of $1.04 at a trading ...
Affymax, Inc. (AFFY): Affymax Likely Worthless: Omontys Kills At Least 9x More ...
Seeking Alpha - Aug 28, 2013
Affymax, Inc. (OTCPK:AFFY) is a shell company that owns potential future royalty and milestone payments associated with the recently recalled drug Omontys (peginesatide).
Affymax Inc. (OTCMKTS:AFFY) Hot Stock in Focus
Equities Focus (registration) - Dec 16, 2014
Affymax, Inc.(OTCMKTS:AFFY) saw a sharp decline in share price in June 2014. Stock plummeted down from $0.69 to $0.11.
Affymax, Inc. (AFFY): Affymax: Emerging Data Supports Conclusion Omontys ...
Seeking Alpha - Nov 12, 2013
The FDA data, combined with the lack of commentary about Omontys on Fresenius' (NYSE:FMS) or Takeda's (OTCPK:TKPHF) latest earnings calls and the cash burn at Affymax (OTCPK:AFFY), all lead us to believe that the end is near for Affymax.
Affymax, Inc. (AFFY): Affymax: Putting The Pieces Together [Amgen, Inc ...
Seeking Alpha - Aug 24, 2013
Affymax's sole drug product is OMONTYS┬« (peginesatide) Injection ("OMONTYS"), which was approved by the FDA in 2012 and well received by the medical community as a treatment for anemia due to chronic kidney disease (CKD) in adult patients on ...
Affymax, Inc. (OTCMKTS:AFFY) Bursts Onto The Charts
HotStocked - Dec 1, 2014
Affymax, Inc. (OTCMKTS:AFFY, AFFY message board) isn't one of the most actively traded companies in the OTC markets.
Affymax, Inc. (AFFY): Affymax: Huge Speculative Upside With Near-Term Risks
Seeking Alpha - Jul 25, 2013
Affymax and its partner, the global Japanese pharma company Takeda (OTCPK:TKPYY) (eighth largest pharma in the world), made the decision to VOLUNTARILY recall OMONTYS in February of this year.
Affymax, Inc. (AFFY): Don't Believe In Affymax - The Stock Is Probably Worthless
Seeking Alpha - Aug 29, 2013
Investors in Affymax (OTCPK:AFFY) would like you to believe that Omontys will make a miraculous comeback and that Affymax will be a major winner. My belief is that the last AFFY article contained multiple factual errors that when refuted show that the ...
The end for Affymax (AFFY)
Seeking Alpha - Jun 24, 2014
With no hope for a return to the market for Omontys, Affymax's (AFFY) BOD approves the liquidation and dissolution of the company, subject to shareholder approval.
Affymax Board Announces Decision to Dissolve the Company - Business Wire (press release)
Affymax Board Approves Dissolving Troubled Company - Genetic Engineering News